This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>
25th November 2026

Company: Chordia Therapeutics Inc
Representative: Chief Executive Officer Hiroshi Miyake
(Security Code: 190A TSE Growth Market)
Contact: IR Manager Ami Kira
MAIL : info@chordiatherapeutics.com

Notice of Commencement of Joint Research with CUePEAK BIO. Co., Ltd.

Chordia Therapeutics Inc. (Head Office: Fujisawa City, Kanagawa Prefecture; CEO: Hiroshi Miyake, "Chordia") and CUePEAK BIO. Co., Ltd. (Head Office: Daejeon, Korea; CEO: Joonsung Hwang, "CUePEAK") have entered into a joint research agreement ("Joint Research") to explore the therapeutic potential of multiple compounds for dermatological diseases. In this Joint Research, Chordia and CUePEAK will investigate the potential of multiple compounds from Chordia's oncology pipeline, including its preclinical GCN2 program for dermatological diseases. The collaboration will combine Chordia's compounds and expertise in drug discovery with CUePEAK's proprietary pharmacological evaluation platforms and specialized expertise in dermatological drug discovery to identify and evaluate potential new therapeutic applications.
Chordia will provide relevant know-how and research materials while CUePEAK will apply its dermatology-focused research platforms to conduct pharmacological and other relevant studies. Based on the research outcomes, the companies will explore opportunities for further development, licensing, and commercialization, subject to separate agreements.

Alongside advancing the exploration of new therapeutic applications through this collaboration, Chordia will continue to explore the possibility of R&D and business development opportunities in other diseases, including oncology.

The impact of this matter on our business results is expected to be minor.

About CUePEAK BIO. Co., Ltd.

CUePEAK is a biotechnology company specializing in drug discovery for dermatological diseases, spun out of the Korea Research Institute of Bioscience and Biotechnology (KRIBB). In addition to its operations in Korea, CUePEAK has established its Japanese subsidiary, CUePEAK Biotech Co., Ltd., based in Yokohama and maintains an R&D base at Shonan Health Innovation Park in Japan. CUePEAK

focuses on precision medicine for dermatological diseases and has expertise in drug repositioning, including exploring drug candidates from other therapeutic areas for potential applications in dermatology. CUePEAK has established proprietary pharmacological evaluation platforms for dermatological diseases, with particular expertise in skin inflammation, pruritus, and skin barrier function, including filaggrin regulation. CUePEAK aims to expand the application of its proprietary drug discovery platform through strategic research collaborations with pharmaceutical and biotechnology companies in Japan and other global markets. For more information, please visit https://cuepeakbio.com.

About Chordia Therapeutics

Chordia Therapeutics is a research and development-stage biopharmaceutical company specializing in oncology with clinical-stage assets, headquartered in Fujisawa City, Kanagawa Prefecture. Chordia's lead asset, rogocekib (CLK inhibitor CTX-712), is under Phase 1/2 clinical study in the US. Rogocekib potentially targets the vulnerability of cancer and is expected to deliver benefits to patients of various types of cancer. In addition to rogocekib, Chordia is engaged in the research and development of several assets, including ocipumaltib (MALT1 inhibitor CTX-177) , CTX-439, a CDK12 inhibitor, and GCN2 inhibitors. For more information, please visit our website https://www.chordiatherapeutics.com/en/.